GVAX for Patients With Pancreatic Cancer
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma.
Clinical Pearls
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma. A phase II study of the vaccine waspresented at the 2014 Gastrointestinal Cancers Symposium.
- GVAX is a whole cell vaccine made of pancreatic cancer cells expressing GM-CSF. GVAX is given with low-dose cyclophosphamide.
- Patients in the study were randomized to receive cyclophosphamide/GVAX followed by CRS-207 or just cyclophosphamide/GVAX. CRS-207 is a modified Listeria bacteria which expresses mesothelin.
- Patients in the cyclophosphamide/GVAX and CRS-207 arm experienced an overall survival benefit of about 2 months (6.1 versus 3.9 months).
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
